deCODE is a biopharmaceutical company applying its discoveries in human genetics to develop diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease.

The company is advancing the clinical development of two compounds for the prevention of heart attack and an anti-platelet compound for the prevention of arterial thrombosis, as well as DNA-based diagnostic tests to predict risk of type 2 diabetes, heart attack, atrial fibrillation/stroke, and prostate and breast cancer.